SoftBank, Bristol Myers Squibb and Hitachi were among Arsenal Biosciences’ $220m round while MegaChips led a $140m round for Morse Micro.

M&A

Pharmaceutical firm Roche has agreed to acquire a portfolio company, Good Therapeutics, which is a US-based self-regulating therapy developer, for $250m in cash and additional earnouts. The company had secured more than $30m in funding from the corporate’s Roche Venture Fund as well as RiverVest Venture Partners, 3×5 Partners, Digitalis Ventures and Codon Capital.

Funding

Company Company description Sector Country Round Round size($m) Deal date Investors
Arsenal Biosciences Programmable cell therapy developer Healthcare US B 220 06/09/2022 SoftBank (SoftBank Vision Fund 2), Bristol Myers Squibb, Hitachi (Hitachi Ventures); Byers Capital,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
Events
GCV Institute: CVC Investment Programs
Dec 3 -
Dec 4, 2024
Online
Events
GCV Connect: Korea 2024
Dec 10 -
Dec 12, 2024
Seoul (South Korea)
Events
GCV Institute: CVC Investment Programs
Jan 28 -
Jan 29, 2025
Online
Events
GCV Institute: CVC Investment Programs
Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)
Events
GCVI Summit 2025
Mar 18 -
Mar 20, 2025
Monterey, CA (USA)
Events
GCV Institute: Landing the Value of Corporate Venturing
May 1 -
May 6, 2025
Online
Events
GCV Symposium 2025
Jun 17 -
Jun 19, 2025
London (UK)
© 2024 Mawsonia Ltd. All rights reserved.
test reg